XML 34 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Information (Tables)
 6 Months Ended
Dec. 31, 2013
Segment Reporting [Abstract]  
Revenue by Reportable Segment
The following tables present revenue for each reportable segment and reconciling items necessary to agree to amounts reported in the condensed consolidated statements of earnings:
 
Three Months Ended December 31
(in millions)
2013
 
2012
Pharmaceutical (1)
$
19,443

 
$
22,747

Medical
2,799

 
2,487

Total segment revenue
22,242

 
25,234

Corporate (2)
(2
)
 
(2
)
Total revenue
$
22,240

 
$
25,232


 
Six Months Ended December 31
(in millions)
2013
 
2012
Pharmaceutical (1)
$
41,256

 
$
46,244

Medical
5,511

 
4,879

Total segment revenue
46,767

 
51,123

Corporate (2)
(4
)
 
(2
)
Total revenue
$
46,763

 
$
51,121


(1)
The decrease in Pharmaceutical segment revenue is primarily due to the expiration of our pharmaceutical distribution contract with Walgreens.
(2)
Corporate revenue consists of the elimination of inter-segment revenue.
Segment Profit by Reportable Segment
The following tables present segment profit by reportable segment and reconciling items necessary to agree to amounts reported in the condensed consolidated statements of earnings:
 
Three Months Ended December 31
(in millions)
2013
 
2012
Pharmaceutical
$
482

 
$
441

Medical
131

 
94

Total segment profit
613

 
535

Corporate
(94
)
 
(29
)
Total operating earnings
$
519

 
$
506


 
Six Months Ended December 31
(in millions)
2013
 
2012
Pharmaceutical
$
916

 
$
841

Medical
238

 
168

Total segment profit
1,154

 
1,009

Corporate
(164
)
 
(46
)
Total operating earnings
$
990

 
$
963
Assets by Reportable Segments
The following table presents total assets for each reportable segment and reconciling items necessary to agree to amounts reported in the condensed consolidated balance sheets at the dates indicated below:
(in millions)
December 31,
2013
 
June 30,
2013
Pharmaceutical (1)
$
14,985

 
$
16,258

Medical
6,558

 
6,521

Corporate
3,466

 
3,040

Total assets
$
25,009

 
$
25,819

(1)
The decrease in Pharmaceutical segment assets is primarily due to the expiration of our pharmaceutical distribution contract with Walgreens.